NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
Go back to NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression| (NASDAQ: NRXP) | Delayed: 4.03 -0.45 (10.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.48 | 52 Week High | $ | |||
| Open | $4.35 | 52 Week Low | $ | |||
| Day High | $4.42 | P/E | N/A | |||
| Day Low | $4.02 | EPS | $ | |||
| Volume | 688,974 | |||||
